Ushering in liquid biopsy for the microsatellite status: Advantages and caveats

Linghua Wang; Jaffer A. Ajani

doi:10.1158/1078-0432.CCR-19-2585

Ushering in liquid biopsy for the microsatellite status: Advantages and caveats

Linghua Wang, Jaffer A. Ajani

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Microsatellite instable tumors often respond to immune checkpoint blockade (ICB), however, tumor tissue is unavailable/insufficient in some patients. Two groups are reporting a blood-based assessment of the microsatellite status validated in tumor tissue and by clinical benefit in patient receiving ICB. Both approaches are highly appealing with a few caveats.

Original language	English (US)
Pages (from-to)	6887-6889
Number of pages	3
Journal	Clinical Cancer Research
Volume	25
Issue number	23
DOIs	https://doi.org/10.1158/1078-0432.CCR-19-2585
State	Published - Dec 1 2019

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-19-2585

Cite this

@article{ab2619a205ec423f8d62f3f6ab111524,

title = "Ushering in liquid biopsy for the microsatellite status: Advantages and caveats",

abstract = "Microsatellite instable tumors often respond to immune checkpoint blockade (ICB), however, tumor tissue is unavailable/insufficient in some patients. Two groups are reporting a blood-based assessment of the microsatellite status validated in tumor tissue and by clinical benefit in patient receiving ICB. Both approaches are highly appealing with a few caveats.",

author = "Linghua Wang and Ajani, {Jaffer A.}",

note = "Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",

year = "2019",

month = dec,

day = "1",

doi = "10.1158/1078-0432.CCR-19-2585",

language = "English (US)",

volume = "25",

pages = "6887--6889",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "23",

}

TY - JOUR

T1 - Ushering in liquid biopsy for the microsatellite status

T2 - Advantages and caveats

AU - Wang, Linghua

AU - Ajani, Jaffer A.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Microsatellite instable tumors often respond to immune checkpoint blockade (ICB), however, tumor tissue is unavailable/insufficient in some patients. Two groups are reporting a blood-based assessment of the microsatellite status validated in tumor tissue and by clinical benefit in patient receiving ICB. Both approaches are highly appealing with a few caveats.

AB - Microsatellite instable tumors often respond to immune checkpoint blockade (ICB), however, tumor tissue is unavailable/insufficient in some patients. Two groups are reporting a blood-based assessment of the microsatellite status validated in tumor tissue and by clinical benefit in patient receiving ICB. Both approaches are highly appealing with a few caveats.

UR - http://www.scopus.com/inward/record.url?scp=85075957704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075957704&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-19-2585

DO - 10.1158/1078-0432.CCR-19-2585

M3 - Article

C2 - 31527165

AN - SCOPUS:85075957704

SN - 1078-0432

VL - 25

SP - 6887

EP - 6889

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 23

ER -

Ushering in liquid biopsy for the microsatellite status: Advantages and caveats

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this